Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 5/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089778 | 0.76 | HASPIN (0.41) | CHEK1CHEK2CDK1SRCCSNK2A2 | |
| SCHEMBL5092742 | 0.75 | CHEK1 (0.39) | NTRK1CHEK1CHEK2CDK1SRC | |
| Trifluoroacetic Acid SCHEMBL5095364 | 0.75 | NTRK1 (0.41) | NTRK1NTRK3NTRK2GSK3BCHEK1 | |
| Trifluoroacetic Acid SCHEMBL5095375 | 0.75 | NTRK1 (0.41) | NTRK1NTRK3NTRK2GSK3BCHEK1 | |
| SCHEMBL5092907 | 0.73 | RET (0.38) | CHEK1CHEK2CDK1SRCCSNK2A2 | |
| Hydrochloric Acid SCHEMBL5101125 | 0.73 | CDC7 (0.36) | CHEK1CHEK2CDK1SRCCSNK2A2 | |
| Hydrochloric Acid SCHEMBL5095503 | 0.73 | CDC7 (0.36) | CHEK1CHEK2CDK1SRCCSNK2A2 | |
| Hydrochloric Acid SCHEMBL5092758 | 0.72 | HTR3A (0.36) | CHEK1CHEK2CDK1SRCCSNK2A2 | |
| SCHEMBL5094471 | 0.72 | CNR1 (0.34) | CHEK1CHEK2CDK1SRCCSNK2A2 | |
| Hydrochloric Acid SCHEMBL5089590 | 0.72 | CDC7 (0.37) | GSK3BCHEK1CHEK2CDK1HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | claimed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | claimed |
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K6, MAP3K1 | NTRK1 835/4885NTRK3 1009/4885NTRK2 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.